Abstract 1580P
Background
There is concern that the incidence of oesophageal adenocarcinoma (OAC) in patients under 50, described as early onset (EO) OAC, may be rising steadily. Epidemiological studies suggest that EO-OAC patients present with higher-stage disease compared to late-onset patients, receive more aggressive treatment but may have poorer survival outcomes. We utilised Whole Genome Sequencing (WGS) and RNA-seq to investigate if EO-OAC represents a distinct biological entity compared to late-onset disease.
Methods
We obtained WGS and clinical data for stage and treatment matched OAC patients who received neoadjuvant chemotherapy prior to surgical resection (n=29 patients ≤50 years and n=144 patients ≥70 years) from the OCCAMS consortium. We performed statistical analysis between age groups using chi-squared testing with FDR correction for copy number aberrations (CNA), insertions and deletions (INDELS) and single nucleotide variants (SNV), assessing gene-level mutations and mutational burden considering coding genes only, prior to assessing 76 OAC driver genes as described by Frankell et al., 2019. Biological pathways between age groups were assessed for n=66 patients using available RNASeq data and Gene Set Enrichment Analysis (GSEA).
Results
Our results indicate that EO-OAC had a lower combined mutational burden (Wilcoxon p=0.0204) and lower indel counts (Wilcoxon p=0.0031) compared to late-onset patients. When considering gene-level mutations for SNV, CNA, INDELS and 76 OAC driver genes (Frankell et al., 2019), multiple analyses showed genes at a nominal p-value <0.05 between age groups yet none reached significance at FDR p-value <0.25. GSEA indicated 179 enriched pathways, several related to immune signalling for EO-OAC at nominal p-value <0.05 and a higher DNA Damage Immune Response (DDIR) assay score in EO-OAC (p=0.012).
Conclusions
Our comparison of early and late-onset OAC using WGS and RNA-seq data highlights the possibility of EO-OAC as a separate biological entity, with potentially enhanced immune signalling. Future work in larger sample cohorts and the investigation of clinically relevant gene and mutational signatures is required to further assess molecular differences between early and late onset OAC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1635P - Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients
Presenter: Giulia Orsi
Session: Poster session 22
1636P - Circulating tumor DNA (ctDNA) profile in patients (pts) with pancreatic cancer (PC): A multicenter experience and challenges for clinical application
Presenter: Francisco Muñoz i Carrillo
Session: Poster session 22
1637P - Early retention of KRAS mutations in cfDNA is an ominous sign for pancreatic cancer patients during chemotherapy: A prospective cohort study
Presenter: Chien-Jui Huang
Session: Poster session 22
1638P - The prognostic and predictive role of class III β-tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma
Presenter: Taha Koray Sahin
Session: Poster session 22
1639P - Feasibility of tumor genomic sequencing on tissue obtained from endoscopic ultrasound in patients with pancreatic cancer
Presenter: Vaia Florou
Session: Poster session 22
1640P - Response monitoring with ctDNA in metastatic pancreatic cancer
Presenter: Jinwoo Ahn
Session: Poster session 22
1642P - Prognostic impact of an immunomorphological signature integrating immune, fibroblastic and tumor markers in a series of 217 resected pancreatic adenocarcinoma patients
Presenter: Franck MONNIEN
Session: Poster session 22
1643P - Clinical outcomes of FOLFIRINOX as front-line therapy in patients with localized pancreatic adenocarcinoma: Asian retrospective study of 781 patients
Presenter: Kyunghye Bang
Session: Poster session 22
1644P - The mutation landscape and evolution pattern of liver or peritoneal metastasis in pancreatic cancer
Presenter: Guoliang Yao
Session: Poster session 22